Latest News

• August 26th, 2008

  Novosom AG acquires exclusive license from Isis Pharmaceuticals, Inc. for CD40-targeted antisense inhibitors >>

• May 14th, 2008

  Novosom granted US and European patents for RNAi-delivering Smarticles^® >>

See how our technology works >>

Business Development

novosom has already secured a number of research collaboration and licensing arrangements around the SMARTICLES^® technology and would be interested in enquiries relating to SMARTICLES^®, the CAGICLES^® technology, reformulation work or the product candidates. If you would like to hear more about these, simply fill in your details on the form below and submit your request:

(Fields you must complete are marked with an asterisk*)

Name*:

Job Title:

Company Name*:

Address 1:

Address 2:

City:

Postcode:

Country:

Email*:

Sector*: Pharmaceutical Biotechnology Service Provider Other

Tel:

Comments*:

Alternatively, you can contact us directly at the following address:

novosom AG
Weinbergweg 22
06120 Halle
Germany
Mail: info[at]novosom.com
Fon.: +49 (0)345 55 59 836
Fax: +49 (0)345 55 59 846

Design: College Hill – Life Sciences

Weinbergweg 22  06120 Halle  Germany  info[at]novosom.com  Fon.: +49 (0)345 55 59 836     Impressum